Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06528301 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
A Phase 1 study of Lymphoma, B-Cell and Chronic Lymphocytic Leukemia (CLL), sponsored by Umoja Biopharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
- 8
- Study locations
NCT06528301 is a Phase 1 study of Lymphoma, B-Cell and Chronic Lymphocytic Leukemia (CLL) that is actively recruiting participants, run by Umoja Biopharma. The registered enrollment target is 106 participants, below the 198-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (46% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT06528301, a Phase 1 study of Lymphoma, B-Cell and Chronic Lymphocytic Leukemia (CLL), is actively recruiting participants, sponsored by Umoja Biopharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Conditions Studied
Interventions
- DRUG rapamycin
- GENETIC UB-VV111
Study Locations (8)
California
- City of Hope - Duarte
Illinois
- The David and Etta Jonas Center for Cellular Therapy - Chicago
Missouri
- Washington University School of Medicine/Siteman Cancer Center - St Louis
Nebraska
- University of Nebraska Medical Center - Omaha
Ohio
- University of Cincinnatti Medical Center - Cincinnati
Washington
- Fred Hutch Cancer Center - Seattle
New South Wales
- Royal North Shore Hospital - Saint Leonards
Victoria
- St. Vincent's Hospital Melbourne - Fitzroy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06528301
The ClinicalTrials.gov registry entry for NCT06528301 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (46% lower). The listed sponsor is Umoja Biopharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lymphoma, B-Cell appearing as the primary indexed condition, and to 2 interventions - of which rapamycin is the first listed.
NCT06528301 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Missouri.
Frequently Asked Questions
What is clinical trial NCT06528301 about?
NCT06528301 is a clinical study titled "A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies". This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
What is the current status of trial NCT06528301?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2025-03-10. Estimated completion is 2029-03.
What conditions does trial NCT06528301 study?
This clinical trial studies the following conditions: Lymphoma, B-Cell, Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL).
What interventions are being tested in trial NCT06528301?
The interventions under investigation include: rapamycin (DRUG), UB-VV111 (GENETIC).
Who is sponsoring clinical trial NCT06528301?
This trial is sponsored by Umoja Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06528301 being conducted?
This trial has 8 study locations across California, Illinois, Missouri, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
RECRUITING · Phase 1
-
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
RECRUITING · Phase 1
-
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.